Australia markets closed
  • ALL ORDS

    7,739.30
    +22.20 (+0.29%)
     
  • AUD/USD

    0.7216
    +0.0006 (+0.08%)
     
  • ASX 200

    7,417.30
    +23.40 (+0.32%)
     
  • OIL

    83.87
    +0.05 (+0.06%)
     
  • GOLD

    1,822.20
    +5.70 (+0.31%)
     
  • BTC-AUD

    59,388.03
    -722.88 (-1.20%)
     
  • CMC Crypto 200

    1,030.42
    +4.69 (+0.46%)
     

ChemoCentryx's (NASDAQ:CCXI) investors will be pleased with their incredible 382% return over the last five years

  • Oops!
    Something went wrong.
    Please try again later.
·3-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Long term investing can be life changing when you buy and hold the truly great businesses. While not every stock performs well, when investors win, they can win big. Don't believe it? Then look at the ChemoCentryx, Inc. (NASDAQ:CCXI) share price. It's 382% higher than it was five years ago. And this is just one example of the epic gains achieved by some long term investors. It's also good to see the share price up 160% over the last quarter. This could be related to the recent financial results, released recently - you can catch up on the most recent data by reading our company report.

So let's assess the underlying fundamentals over the last 5 years and see if they've moved in lock-step with shareholder returns.

Check out our latest analysis for ChemoCentryx

Because ChemoCentryx made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually expect strong revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

For the last half decade, ChemoCentryx can boast revenue growth at a rate of 8.1% per year. That's a fairly respectable growth rate. However, the share price gain of 37% during the period is considerably stronger. It might not be cheap but a (long-term) growth stock like this is usually well worth taking a closer look at.

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

earnings-and-revenue-growth
earnings-and-revenue-growth

We consider it positive that insiders have made significant purchases in the last year. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. So it makes a lot of sense to check out what analysts think ChemoCentryx will earn in the future (free profit forecasts).

A Different Perspective

While the broader market gained around 28% in the last year, ChemoCentryx shareholders lost 32%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. On the bright side, long term shareholders have made money, with a gain of 37% per year over half a decade. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider risks, for instance. Every company has them, and we've spotted 1 warning sign for ChemoCentryx you should know about.

ChemoCentryx is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting